Biotechnology company Seattle Genetics Inc (Nasdaq:SGEN) stated on Tuesday that it recorded a net loss of USD79.2m (USD.49 per diluted share) for the second quarter ended 30 June 2019.
This is a dip in earnings when compared with net income of USD6.3m (USD.47 per diluted share) for the second quarter of 2018.
The company said the net loss in the second quarter of 2019 included a net investment loss primarily associated with its common stock holdings.
Total revenues of USD218.4m were generated in the second quarter ended 30 June 2019, a growth over USD170.2m for the same period in 2018.
Research and Development (R&D) expenses of USD163.9m were recorded in the second quarter 2019, a rise versus R&D of USD122.9m in the second quarter of 2018. The increases reflect additional investment in the company's late-stage pipeline including enfortumab vedotin, tucatinib and tisotumab vedotin.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation